« Return to News | Drug Sponsors

MedImmune aquires Alphacore Pharma

Wednesday, April 3, 2013 02:20 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has acquired AlphaCore Pharma, an Ann Arbor, Mich.-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

LCAT, an enzyme in the bloodstream, is a key component in the reverse cholesterol transport (RCT) system, which is thought to play a major role in driving the removal of cholesterol from the body and may be critical in the management of high-density lipoprotein (HDL) cholesterol levels. The LCAT enzyme could also play a role in a rare, hereditary disorder called familial LCAT deficiency (FLD) in which the LCAT enzyme is absent.

Cardiovascular and metabolic disease is a core therapy area for AstraZeneca's small and large molecule research.

"Cardiovascular disease is projected to remain the single leading cause of death worldwide over the next decade and beyond,” said Dr. Bahija Jallal, executive vice president, MedImmune. “Through novel approaches like LCAT, we hope to shift the treatment paradigms in this area to help prevent and treat these conditions."

In 2012, results from a phase I clinical trial of ACP-501 met the primary safety and tolerability endpoints. No serious adverse events were reported. ACP-501 also met the study's secondary endpoints by rapidly and substantially elevating HDL cholesterol. The data from this study support ongoing clinical development of ACP-501.

Financial details of the acquisition were not disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.